Live Breaking News & Updates on Agenus Inc

Stay updated with breaking news from Agenus inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

GSK : DO NOT COURIER US FDA approves expanded age indication for GSK's Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk

Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes1

Clinical development programme continues to. ....

United States , Annr Falsey , Tony Wood , Conference On Vaccinology Research , Saponiqx Inc , Forum Infectious Diseases , University Of Rochester School Medicine , Drug Administration , Centers For Disease , National Foundation For Infectious Diseases , Antigenics Inc , Agenus Inc , Respiratory Syncytial Virus , Chief Scientific Officer , Rochester School , Syncytial Virus Vaccine , Risk Factors , Severe Respiratory Syncytial Virus Disease , National Foundation , Infectious Diseases , Annual Conference , Vaccinology Research , Medically Attended , Systematic Review , Open Forum Infectious Diseases , Clinical Infectious Diseases ,

US FDA Approves Expanded Age Indication for GSK's AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk

Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes1

Clinical development program continues to evaluate safety and immunogenicity. ....

United States , Tony Wood , Annr Falsey , National Foundation For Infectious Diseases , Drug Administration , University Of Rochester School Medicine , Centers For Disease , Antigenics Inc , Conference On Vaccinology Research , Saponiqx Inc , Agenus Inc , Forum Infectious Diseases , Respiratory Syncytial Virus , Business Wire , Chief Scientific Officer , Rochester School , Respiratory Syncytial Virus Vaccine , Syncytial Virus Vaccine , Safety Information , West Road , Risk Factors , Severe Respiratory Syncytial Virus Disease , National Foundation , Infectious Diseases , Vaccinology Research , Medically Attended ,

Agenus' (AGEN) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Agenus (NASDAQ:AGEN – Free Report) in a research report released on Friday, Benzinga reports. HC Wainwright currently has a $40.00 price target on the biotechnology company’s stock. Other equities research analysts have also recently issued research reports about the stock. StockNews.com began coverage on shares of […] ....

United States , Agenus Inc , First Command Advisory Services Inc , Jump Financial , Principal Financial Group Inc , Barclays Plc , Swiss National Bank , Free Report , Get Free Report , Financial Group , Command Advisory Services , National Bank , Retrocyte Display , Agenus Daily ,

HC Wainwright Reaffirms "Buy" Rating for Agenus (NASDAQ:AGEN)

HC Wainwright reiterated their buy rating on shares of Agenus (NASDAQ:AGEN – Free Report) in a research report released on Friday morning, Benzinga reports. HC Wainwright currently has a $40.00 price objective on the biotechnology company’s stock. AGEN has been the subject of a number of other reports. B. Riley reduced their price objective on […] ....

United States , Wealth Advisors , First Command Advisory Services Inc , Agenus Inc , Exchange Traded Concepts , Ables Iannone Moore Associates Inc , Free Report , Get Free Report , Iannone Moore , Command Advisory Services , Traded Concepts , Retrocyte Display , Agenus Daily ,

Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Eric Olson , Compensation Committee Of Agenu Board Directors , Agenus Inc , Compensation Committee , Agenu Board , Equity Plan , Nasdaq Listing Rule , Grant Date ,